Skip to main content
. Author manuscript; available in PMC: 2022 Sep 14.
Published in final edited form as: Gastroenterology. 2020 May;158(6):1789–1810.e15. doi: 10.1053/j.gastro.2020.02.039

Table 17.

Knowledge and Evidence Gaps in the Management of Eosinophilic Esophagitis

Use of uniform end points among clinical trials to facilitate meaningful comparisons between therapies
Understanding the mechanisms and management of persistent symptoms in spite of histologic remission
Defining the extent and implications of variations in clinical outcomes for individual patients
Head-to-head studies comparing therapies to inform an algorithmic approach
Effectiveness of combinations of treatments (eg, PPI + diet, PPI + steroids, steroids + diet, steroids + dilation)
Prospective data on the natural history of EoE to inform decisions regarding maintenance therapy
Longer-term studies evaluating the efficacy of maintenance medical and diet therapies
Measurement of quality of life and nutritional status as outcomes
Use of biomarkers for diagnosis and monitoring
Validation of office-based, nonendoscopic disease-monitoring methods for EoE activity
Appropriate timing of esophageal dilation in relation to use of medical or diet therapy (eg, should esophageal dilation only be performed after initiation of medical or diet therapy)
Using clinical history of symptoms with food exposure to guide therapy in EoE
Interaction between oral immunotherapy for food allergy and EoE
Impact of other associated atopic diseases (IgE-mediated food allergy, pollen food allergy, atopic dermatitis, asthma, allergic rhinitis)
Effectiveness of environmental allergen avoidance and immunotherapy